Summary of opinion: Frontpro (previously Afoxolaner Merial) Positive
Submitted by Anonymous (not verified) on 7 November 2025 - 14:00
Summary of opinion: Frontpro (previously Afoxolaner Merial) Positive
Summary of opinion: Frontpro (previously Afoxolaner Merial) Positive
Summary of opinion: Mhyosphere PCV ID, 06/11/2025 Positive
Withdrawn application: Dupixent, 18/02/2025
Personalised medicine in oncology
Cancer medicines
CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
Union Product Database: release notes
Release notes - production release version 1.7.2541 - 7 November 2025 - Veterinary Medicinal Products Regulation: Union Product Database
Clinical Trial Information System (CTIS) - Sponsor handbook
Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Date of authorisation: 19/01/2006, Revision: 41, Status: Authorised